Business context and reporting period
This is PerkinElmer, Inc.’s unaudited Form 10-Q for the quarter ended September 29, 2013, with comparisons to September 30, 2012; it also reports nine-month year-to-date results. The filing names PerkinElmer as the issuer, not Revvity, Inc., as stated in the request metadata. The company operated through Human Health and Environmental Health segments.
Key financial results
Amounts are in millions of dollars except per-share data and percentages.
| Metric | Q3 2013 | Q3 2012 | 9M 2013 | 9M 2012 |
|---|---|---|---|---|
| Revenue | 524.3 | 509.6 | 1,573.0 | 1,542.3 |
| Operating income | 57.2 | 43.2 | 132.8 | 129.4 |
| Income from continuing operations | 40.3 | 29.0 | 99.5 | 84.6 |
| Net income | 40.2 | 29.6 | 100.3 | 85.8 |
| Diluted EPS | $0.36 | $0.26 | $0.88 | $0.75 |
| Gross margin | 44.5% | 45.3% | 44.5% | 45.5% |
- Revenue and segment performance: Q3 revenue increased 3% year over year; nine-month revenue rose 2%. Q3 Human Health revenue grew 2% and Environmental Health grew 4%. For nine months, Human Health operating income increased to $99.0 million from $83.0 million, while Environmental Health operating income declined to $61.9 million from $77.9 million.
- Margins and costs: Q3 operating margin rose to approximately 10.9% from 8.5%; management attributed the improvement chiefly to restructuring, cost containment and productivity efforts. Gross margin fell 74 basis points in Q3 and 94 basis points year to date, reflecting pricing pressure, unfavorable mix and inflation, partly offset by volume and productivity gains.
- Cash flow: Nine-month cash from continuing operating activities was $87.0 million, down from $113.8 million. Working-capital cash use included a $31.8 million inventory increase and a $6.0 million reduction in accounts payable; accrued expenses and other items also reduced cash, largely due to payment timing. Capital expenditures were $31.6 million. Cash and cash equivalents fell to $132.3 million from $171.4 million at year-end 2012.
- Liquidity and debt: Current assets were $948.4 million and current liabilities $589.4 million. Debt totaled approximately $935.9 million, including $248.0 million drawn on the revolving facility, $647.4 million carrying value of senior notes and $40.5 million of financing lease obligations. The $700 million revolver had $440 million available; the company reported compliance with applicable covenants.
- Capital returns: Nine-month financing cash outflow included $127.2 million of share repurchases and $23.7 million of dividends. The quarterly dividend was $0.07 per share.
Material changes, outlook and commentary
- Revenue growth was modest, while profit increased more quickly, particularly in Q3, with lower SG&A and restructuring costs helping operating results. Nine-month Environmental Health operating income weakened despite segment revenue growth, amid unfavorable pricing and product mix and growth-related spending.
- The nine-month income tax benefit from continuing operations was $4.0 million, versus an $8.7 million provision in 2012. Management cited $15.6 million of discrete tax benefits, mainly reserve reversals and tax matter resolutions; the tax benefit materially affected the year-to-date effective tax rate.
- Management expected annual savings exceeding $3 million from 2013 restructuring actions beginning in fiscal 2015, and exceeding $11 million from 2012 actions beginning in fiscal 2014. The 2013 actions included planned workforce reductions, notably 265 employees under the Q2 plan. No specific full-year revenue or EPS guidance is provided in the supplied filing text.
- Management described demand opportunities in disease screening, research informatics, laboratory services and regulated environmental testing, while noting weaker medical imaging and certain research-market demand. Approximately 60% of the business was conducted outside the United States, exposing results to currency and international-market conditions.
- In August 2013, the company sold a Boston facility for $49.5 million and leased it back for an initial 15-year term, with extension options. It deferred $26.5 million of gain for recognition over the initial lease term. The cash-flow statement reports $52.2 million of net proceeds from property dispositions.
Risks, contingencies and unusual items
- Gross-margin pressure, volatile customer orders, government and research funding uncertainty, foreign exchange exposure, competition, supplier concentration and execution of product development and restructuring are identified risks. The filing also highlights substantial debt, variable-rate exposure and dependence on access to credit.
- The Enzo patent and business-practices litigation was expected to go to trial in early 2014. Management said it was contesting the matter and did not expect a material adverse financial effect, but noted the outcome was uncertain.
- The company recorded $6.9 million for known environmental remediation matters; it noted that actual costs could exceed accruals, though it did not expect a material difference. Other ordinary-course claims were also subject to uncertainty.
- Unrecognized tax benefits were $48.5 million; approximately $11.5 million, including related interest and penalties and net of tax benefits, could be resolved within 12 months, according to management.
- The annual goodwill and indefinite-lived intangible impairment tests found no impairment as of January 1, 2013. Goodwill was $2.13 billion and net intangible assets were $481.4 million at quarter-end, making future impairment assumptions relevant.
Most important facts for investors to verify
- Confirm the issuer and period: the filing is PerkinElmer’s Q3 2013 10-Q, not a filing naming Revvity, Inc.
- Assess whether the decline in gross margin and nine-month Environmental Health operating income is temporary or reflects persistent pricing and mix pressure.
- Reconcile operating cash-flow weakness with working-capital movements, pension contributions, tax payments and prepaid royalties; monitor inventory levels and cash conversion.
- Review debt maturities, revolver availability, covenant headroom and the funding impact of repurchases, dividends, lease commitments and pension contributions.
- Track whether projected restructuring savings are realized and whether litigation, tax, environmental or goodwill matters develop beyond recorded estimates.